COMPASS Pathways (CMPS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
15 Apr, 2026Executive summary
The 2026 Annual General Meeting (AGM) will be held on May 27, 2026, in London, with proxy materials distributed to shareholders and ADS holders as of April 6, 2026.
Shareholders are encouraged to vote on ten ordinary resolutions, including director elections, auditor appointments, remuneration reports, and executive compensation.
The Board unanimously recommends voting in favor of all resolutions, viewing them as aligned with the company's best interests.
Voting matters and shareholder proposals
Resolutions include re-election/election of four directors, re-appointment and ratification of PricewaterhouseCoopers LLP as auditors, authorization of auditor remuneration, receipt of annual accounts, and advisory votes on remuneration and executive compensation.
All resolutions require a simple majority; advisory votes on remuneration and compensation are non-binding but will be considered by the Board.
Shareholders may submit proposals for future meetings and have rights to call general meetings under UK law.
Board of directors and corporate governance
The Board is divided into three classes with staggered terms; current nominees include Justin Gover, Daphne Karydas, Kathleen Tregoning, and Jeffrey Jonas.
Board committees include Audit and Risk, Compensation and Leadership Development, Nominating and Corporate Governance, and Scientific Committees, all composed of independent directors.
The Board separates the roles of Chair and CEO and conducts annual self-evaluations.
Shareholder communications and director nomination processes are formalized.
Latest events from COMPASS Pathways
- COMP360 shows rapid, durable efficacy in TRD and PTSD, supporting late-stage trials and commercialization.CMPS
KOL Event9 Jul 2026 - Phase III data for COMP360 in TRD is imminent, with commercial and PTSD program plans progressing.CMPS
TD Cowen 45th Annual Healthcare Conference9 Jul 2026 - Phase 3 COMP360 trials advance as net loss widens but cash runway extends into 2026.CMPS
Q2 20248 Jul 2026 - Q1 net loss narrowed, liquidity surged, and pivotal TRD trial results expected late June.CMPS
Q1 20258 Jul 2026 - COMP360 delivers rapid, durable efficacy in TRD, with 39% response and 2027 launch targeted.CMPS
Study result7 Jul 2026 - COMP360 advances rapidly in depression and PTSD, with strong data, regulatory momentum, and market readiness.CMPS
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Rolling NDA review, CNPV, and $466M cash position support accelerated COMP360 launch.CMPS
Q1 202618 May 2026 - COMP360 achieved rapid, durable efficacy in TRD, with launch readiness and strong IP protection.CMPS
Investor presentation13 May 2026 - Regulatory momentum and clinical advances are driving rapid commercialization of psychedelic therapies.CMPS
Needham Virtual Psychedelics Forum28 Apr 2026